

Disclaimer :

The Competition DG makes the information provided by the notifying parties in section 1.2 of Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudices the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.

M.8572 - PAMPLONA CAPITAL / PAREXEL

SECTION 1.2

Description of the concentration

The notified concentration involves the proposed acquisition by fund(s) managed and advised by Pamplona Capital Management LLP and its affiliates (“**Pamplona Capital**”) of sole control of Parexel International Corporation (“**Parexel**”) (the “**Proposed Transaction**”) within the meaning of Article 3(1)(b) of the EU Merger Regulation.

Pamplona Capital is a global private equity investment firm that provides an alternative investment platform across private equity, fund of hedge funds and single manager hedge fund investments.

Parexel is a biopharmaceutical outsourcing services company, providing a broad range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization and advanced technology products and services to the worldwide pharmaceutical, biotechnology and medical device industries.